MNTA Momenta Pharmaceuticals, Inc.

18.15
+0.00  (0%)
Previous Close 18.15
Open 18.20
Price To book 3.46
Market Cap 1.28B
Shares 70,541,000
Volume 637,912
Short Ratio 4.89
Av. Daily Volume 805,214

SEC filingsSee all SEC filings

  1. 8-K - Current report 17923411
  2. CT ORDER - Confidential treatment order 17892640
  3. 8-K - Current report 17883289
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 17819020
  5. 8-K - Current report 17802978

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial met primary endpoint - November 29, 2016.
M923
Moderate-to-severe chronic plaque psoriasis
Filed 2007. Approved April 16 2015.
Generic Copaxone
Multiple sclerosis
Phase 2 development discontinued due to poor efficacy shown
Necuparanib (MOM-M402-103)
Advanced metastatic pancreatic cancer

Latest News

  1. Mylan In FDA Limbo On Generic Multiple Sclerosis Drug
  2. Implied Volatility Surging for Momenta Pharmaceuticals (MNTA) Stock Options
  3. ETFs with exposure to Momenta Pharmaceuticals, Inc. : June 12, 2017
  4. Momenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017
  5. Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 38th Annual Global Healthcare Conference
  6. Why Is Momenta Pharmaceuticals (MNTA) Down 9.7% Since the Last Earnings Report?
  7. Momenta Pharmaceuticals Appoints Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer
  8. Novartis CEO sees no need for big takeover
  9. UPDATE -- Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
  10. Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
  11. Edited Transcript of MNTA earnings conference call or presentation 2-May-17 2:00pm GMT
  12. Momenta Pharmaceuticals, Inc. Looks for Some Momentum
  13. Momenta (MNTA) Q1 Loss Narrower than Expected, Sales Beat
  14. Momenta Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MNTA) : May 2, 2017
  15. Momenta reports 1Q loss
  16. Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results
  17. Investor Network: Momenta Pharmaceuticals, Inc. to Host Earnings Call
  18. Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MNTA-US : May 1, 2017
  19. Momenta Pharmaceuticals to Webcast Presentation at the Deutsche Bank 42nd Annual Health Care Conference
  20. Momenta Pharmaceuticals Announces Date of First Quarter 2017 Financial Results Conference Call and Webcast

SEC Filings

  1. 8-K - Current report 17923411
  2. CT ORDER - Confidential treatment order 17892640
  3. 8-K - Current report 17883289
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 17819020
  5. 8-K - Current report 17802978
  6. 8-K - Current report 17799379
  7. DEF 14A - Other definitive proxy statements 17786330
  8. 8-K - Current report 17697962
  9. 8-K - Current report 17673913
  10. CT ORDER - Confidential treatment order 17662030